NVCR News and Press, NovoCure Limited From 04/30/19

The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning The International Journal of Radiation Oncology, Biology, Physics, known in the field as the Red Journal, is the official journa...

Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer Novocure (NASDAQ: NVCR) announced today the publication of its 2018 Annual Report featuring its vision, mission and values, employee stories and videos, business highligh...

The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta. The grants represent a joint effort between Novocure (NASDAQ: NVCR) and the AACR to promote and support i...

Novocure (NASDAQ:NVCR) announced today that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended Ma...

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer Ovarian cancer is the fifth leading cause of cancer death among women Novocure (NASDAQ: NVCR) announced today that it has initiated IN...

A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment The volume of Tumor Treating Fields presentations marks a record number of abstracts for Novocure at this conference Novocure (NAS...

Novocure (NASDAQ: NVCR ) Chief Science Officer and Head of R&D, Dr. Eilon Kirson will retire effective May 1, to spend more time with his family. More news on: NovoCure Limited, Healthcare stocks news, Read more ...

Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019. Dr. Kirson will step away from the healthcare industry and frequent international travel to spend more time with hi...

Novocure (NASDAQ:NVCR) announced today that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29 th Annual Healthcare Conference on March 20, 2019, in New York City. Mr. Groenhuysen’s presentation will begin at 10:55 a.m. EDT. Mr...

NovoCure (NVCR) Q4 2018 Earnings Conference Call February 28, 2019 8:00 AM ET Company Participants Ashley Cordova – Senior Vice President-Finance and Investor Relations Bill Doyle – Executive Chairman Wilco Groenhuysen – Chief Financial Officer Eilon Kirson...